Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.42 |
| ▸ | LATS1 | O95835 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.34 |
| ▸ | CCKAR | P32238 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 3/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2318455 | 0.89 | PTGDR2 (0.34) | PTGDR2LATS1L3MBTL1PCSK9BRD4 | |
| SCHEMBL2322259 | 0.86 | PTGDR2 (0.39) | PTGDR2LATS1L3MBTL1 | |
| SCHEMBL2319229 | 0.86 | LATS1 (0.35) | PTGDR2LATS1L3MBTL1PCSK9BRD4 | |
| SCHEMBL2315327 | 0.84 | LMNA (0.43) | PTGDR2METPCSK9BRD4CDK1 | |
| SCHEMBL1932988 | 0.84 | PCSK9 (0.35) | PTGDR2PCSK9BRD4 | |
| SCHEMBL2314750 | 0.83 | PTGS1 (0.37) | PTGDR2LATS1L3MBTL1BRD4 | |
| SCHEMBL2317803 | 0.82 | PCSK9 (0.38) | PTGDR2L3MBTL1PCSK9CDK2CCNT1 | |
| SCHEMBL2319582 | 0.82 | EED (0.39) | METGSK3BPIM1CDK9CDK5 | |
| SCHEMBL2319238 | 0.82 | CYP11B1 (0.39) | PTGDR2LATS1L3MBTL1 | |
| SCHEMBL1933394 | 0.82 | PCSK9 (0.34) | PTGDR2PCSK9BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | CCNI, IL2, IL4I1 | PTGDR2 237/4885LATS1 3397/4885L3MBTL1 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.